Deals

Oct. 28 Quick Takes: Mirati raises $800M on KRAS data; BMS-insitro, Novartis-Molecular Partners, Genecast, Gracell, PureTech, Cerevel, Biodesix  

Adagrasib readout helps Mirati build war chest
Response rate data in the closely-watched KRAS inhibitor race helped Mirati Therapeutics Inc. (NASDAQ:MRTX) raise $800 million in a follow-on via the sale of 4 million shares at $202 per share. Mirati’s